O076 Single-centre experience with administration of neoadjuvant chemotherapy for breast cancer patients – a retrospective analysis over a 11- year period

Abstract Introduction Neoadjuvant chemotherapy (NACT) has been established in down-staging tumours, allowing breast conserving surgery. Additionally, NACT informs treatment decisions guided by tumour response. Pathological complete response (pCR) correlates with disease-free survival. It is known that rates vary according to biological subtype. This retrospective analysis aimed analyse the rate of pCR post cancer subtypes. Methods A usage was conducted from January 2011 December 2021. Clinical data patients who received were collected using local Breast Unit database. included patient demographics, menopausal status, size tumour, type surgical procedure, axillary histopathology details pathological and time and/or systemic recurrence. Results 531 for between 288/531 (54.2%) pre-menopausal. There an increase subtypes (Triple Negative, triple positive & Her 2 positive) receiving over years. 202/538 (37.5%) cancers achieved NACT. higher grade 3 tumours (41.9%) compared 1 (28.8%) or (28.8%). Triple negative HER2 +ve had highest (45.5% 60.3% respectively). Conclusion Patients human epidermal growth factor receptor (HER)2-positive triple-negative are good candidates neoadjuvant as they have probability achieving pCR. Future studies being determine how anticipate which her2+ will achieve